Neurological and psychiatric disorders cause immense suffering and societal strain across the globe and their treatment remains a severe unmet need. Genentech is working to discover and develop transformative medicines for patients with major diseases of the nervous system. Presently we're focused on neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), as well as pain.
By using a multidisciplinary approach and a wide range of technologies, we seek to unravel the fundamental mechanisms underlying the biology and the diseases of the nervous system, and to translate these discoveries into innovative therapies for neurological disorders.
Stopping the spread of tau through the brain may help us in our fight against Alzheimer’s disease.
Genentech scientists have found that a protein called DLK may play a role in many types of neurodegeneration, with implications for diseases like Alzheimer’s and ALS.
Many pain medicines were discovered either by accident or by exploring traditional remedies; we're trying to understand the biology of pain using target-based drug discovery.
Researchers from Genentech made a significant discovery about the underlying biology of Parkinson’s disease.